Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma
Abstract Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and L...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-55614-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559229930930176 |
|---|---|
| author | Matías S. Mendeville Jurriaan Janssen G. Tjitske Los-de Vries Erik van Dijk Julia Richter Marcel Nijland Margaretha G. M. Roemer Phylicia Stathi Nathalie J. Hijmering Reno Bladergroen Diego A. Pelaz Arjan Diepstra Corinne J. Eertink Coreline N. Burggraaff Yongsoo Kim Pieternella J. Lugtenburg Anke van den Berg Alexandar Tzankov Stefan Dirnhofer Ulrich Dührsen Andreas Hüttmann Wolfram Klapper Josée M. Zijlstra Bauke Ylstra Daphne de Jong |
| author_facet | Matías S. Mendeville Jurriaan Janssen G. Tjitske Los-de Vries Erik van Dijk Julia Richter Marcel Nijland Margaretha G. M. Roemer Phylicia Stathi Nathalie J. Hijmering Reno Bladergroen Diego A. Pelaz Arjan Diepstra Corinne J. Eertink Coreline N. Burggraaff Yongsoo Kim Pieternella J. Lugtenburg Anke van den Berg Alexandar Tzankov Stefan Dirnhofer Ulrich Dührsen Andreas Hüttmann Wolfram Klapper Josée M. Zijlstra Bauke Ylstra Daphne de Jong |
| author_sort | Matías S. Mendeville |
| collection | DOAJ |
| description | Abstract Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index. For all subtypes, adverse prognostic value of i/eot-PET-positive status is confirmed. Consistent with frequent primary refractory disease, only 67% C2 patients become eot-PET-negative versus 81-88% for other subtypes. Indicative of high relapse rates, outcome of C5 i/eot-PET-negative patients remains significantly worse in HOVON-84, which trend validates in the PETAL and SAKK38-07 trials (NCT00544219). These results show the added value of integrated genetic subtyping and PET monitoring for prognostic stratification and subtype-specific trial design. |
| format | Article |
| id | doaj-art-9c5f1ec906f3465dbce7688cf4ad9796 |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-9c5f1ec906f3465dbce7688cf4ad97962025-01-05T12:38:57ZengNature PortfolioNature Communications2041-17232025-01-0116111210.1038/s41467-024-55614-yIntegrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphomaMatías S. Mendeville0Jurriaan Janssen1G. Tjitske Los-de Vries2Erik van Dijk3Julia Richter4Marcel Nijland5Margaretha G. M. Roemer6Phylicia Stathi7Nathalie J. Hijmering8Reno Bladergroen9Diego A. Pelaz10Arjan Diepstra11Corinne J. Eertink12Coreline N. Burggraaff13Yongsoo Kim14Pieternella J. Lugtenburg15Anke van den Berg16Alexandar Tzankov17Stefan Dirnhofer18Ulrich Dührsen19Andreas Hüttmann20Wolfram Klapper21Josée M. Zijlstra22Bauke Ylstra23Daphne de Jong24Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Hematopathology Section and Lymph Node Registry University Hospital Schleswig-Holstein, Campus KielDepartment of Hematology University of Groningen, University Medical Centre GroningenDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology and Medical Biology University of Groningen, University Medical Centre GroningenDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center RotterdamDepartment of Pathology and Medical Biology University of Groningen, University Medical Centre GroningenInstitute of Pathology, University of Basel and University Hospital BaselInstitute of Pathology, University of Basel and University Hospital BaselDepartment of Hematology, University Hospital EssenDepartment of Hematology, University Hospital EssenDepartment of Pathology, Hematopathology Section and Lymph Node Registry University Hospital Schleswig-Holstein, Campus KielDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, location VUmcAbstract Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index. For all subtypes, adverse prognostic value of i/eot-PET-positive status is confirmed. Consistent with frequent primary refractory disease, only 67% C2 patients become eot-PET-negative versus 81-88% for other subtypes. Indicative of high relapse rates, outcome of C5 i/eot-PET-negative patients remains significantly worse in HOVON-84, which trend validates in the PETAL and SAKK38-07 trials (NCT00544219). These results show the added value of integrated genetic subtyping and PET monitoring for prognostic stratification and subtype-specific trial design.https://doi.org/10.1038/s41467-024-55614-y |
| spellingShingle | Matías S. Mendeville Jurriaan Janssen G. Tjitske Los-de Vries Erik van Dijk Julia Richter Marcel Nijland Margaretha G. M. Roemer Phylicia Stathi Nathalie J. Hijmering Reno Bladergroen Diego A. Pelaz Arjan Diepstra Corinne J. Eertink Coreline N. Burggraaff Yongsoo Kim Pieternella J. Lugtenburg Anke van den Berg Alexandar Tzankov Stefan Dirnhofer Ulrich Dührsen Andreas Hüttmann Wolfram Klapper Josée M. Zijlstra Bauke Ylstra Daphne de Jong Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma Nature Communications |
| title | Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma |
| title_full | Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma |
| title_fullStr | Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma |
| title_full_unstemmed | Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma |
| title_short | Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma |
| title_sort | integrating genetic subtypes with pet scan monitoring to predict outcome in diffuse large b cell lymphoma |
| url | https://doi.org/10.1038/s41467-024-55614-y |
| work_keys_str_mv | AT matiassmendeville integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT jurriaanjanssen integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT gtjitskelosdevries integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT erikvandijk integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT juliarichter integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT marcelnijland integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT margarethagmroemer integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT phyliciastathi integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT nathaliejhijmering integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT renobladergroen integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT diegoapelaz integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT arjandiepstra integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT corinnejeertink integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT corelinenburggraaff integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT yongsookim integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT pieternellajlugtenburg integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT ankevandenberg integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT alexandartzankov integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT stefandirnhofer integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT ulrichduhrsen integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT andreashuttmann integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT wolframklapper integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT joseemzijlstra integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT baukeylstra integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma AT daphnedejong integratinggeneticsubtypeswithpetscanmonitoringtopredictoutcomeindiffuselargebcelllymphoma |